Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
To assess the primary effects and safety of camrelizumab (SHR-1210) plus apatinib for
downstaging/bridging of HCC before liver transplantation.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Zhejiang University
Collaborators:
First Hospital of Jilin University Huashan Hospital Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Shulan (Hangzhou) Hospital The First Affiliated Hospital of Zhengzhou University The First Hospital of Jilin University Third Affiliated Hospital, Sun Yat-Sen University Tianjin First Central Hospital West China Hospital